{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:40:03Z","timestamp":1767840003907,"version":"3.49.0"},"reference-count":1,"publisher":"S. Karger AG","issue":"Suppl. 1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[1999]]},"abstract":"<jats:p>Three published clinical trials of the efficacy of amphotericin B colloidal dispersion (ABCD) against infections caused by &lt;i&gt;Aspergillus&lt;\/i&gt; spp were reviewed. A total of 376 patients was treated. Systemic aspergillosis was identified in 67 evaluable patients. Overall, a complete or partial response was achieved in 47.8% of the evaluable patients, although there were substantial differences in the response rates between studies. Reasons for recruitment caused a marked difference in response rates. The overall response rate for ABCD in patients in which conventional amphotericin B (CAB) was contra-indicated or had previously failed was 34.3%, whereas the response rate in bone marrow transplant (BMT) or patients with renal impairment was 57.9 and 62.5% respectively. The efficacy of ABCD at doses of 4\u00a0mg\/kg\/day appears to be at least as good as in studies using CAB. The levels of renal toxicity were low at a dose of 4\u00a0mg\/kg\/day. Dose-limiting studies indicate that dosages can be safely increased to 7.5\u00a0mg\/kg\/day creating opportunity for improved efficacy.<\/jats:p>","DOI":"10.1159\/000048468","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T13:07:10Z","timestamp":1050412030000},"page":"34-38","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Efficacy of Amphotericin B Colloidal Dispersion against Infections Caused by &lt;i&gt;Aspergillus&lt;\/i&gt; spp"],"prefix":"10.1159","volume":"45","author":[{"given":"M.","family":"Gurwith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[1999,7,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.149.11.2533"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:03:51Z","timestamp":1745467431000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000048468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"references-count":1,"journal-issue":{"issue":"Suppl. 1","published-online":{"date-parts":[[1999,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000048468","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999]]}}}